Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (141-150 of 232) with videos related to

Pageof 24
Sort By:
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma|March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemiaKaren W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Modernizing Eligibility Criteria for Molecularly Driven TrialsEdward S Kim, David Bernstein, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinomaWan-Teck Lim, Quan-Sing Ng, Percy Ivy, et al.
Pageof 24

Showing results (141-150 of 232) with videos related to

Sort By:
Pageof 24
Haematologica|December 24, 2013
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasmsJoshua F Zeidner, Judith E Karp, Amanda L Blackford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2013
Cediranib for metastatic alveolar soft part sarcomaShivaani Kummar, Deborah Allen, Anne Monks, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Leukemia & Lymphoma|March 12, 2014
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemiaKaren W L Yee, John M Storring, Rena Buckstein, et al.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Modernizing Eligibility Criteria for Molecularly Driven TrialsEdward S Kim, David Bernstein, Susan G Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignanciesSuresh S Ramalingam, Merrill J Egorin, Ramesh K Ramanathan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2011
A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinomaWan-Teck Lim, Quan-Sing Ng, Percy Ivy, et al.
Pageof 24